{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:23:18Z","timestamp":1771240998359,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n Aim<\/jats:title>\n To characterize the long\u2010term adverse events (AEs) observed in patients who received lenvatinib.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We longitudinally assessed long\u2010term AEs in patients with advanced or metastatic radioiodine\u2010refractory differentiated thyroid cancer who had received lenvatinib for more than 1 year. AEs were graded according to the National Cancer Institute Common Terminology Criteria for AEs. Grade 2 AEs were defined as intolerable if a patient complained of distress.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seventeen patients were treated for more than 1 year. The median age was 69 years. The median duration of lenvatinib treatment was 40 months. Notable intolerable grade 2 and 3 AEs were developed in the following order: hypertension (median day 18; range, day 1\u2013131), diarrhea (median, day 27; range, day 4\u20131205), hand\u2010foot skin reaction (median, day 33; range, day 20\u2013582), platelet decrease (median, day 57; range, day 15\u2013427), proteinuria (median, day 72; range, day 18\u20131772), anorexia (median, day 319; range, day 57\u20131541), and chronic kidney disease (CKD) (median, day 715; range, day 274\u20131296). After 2 years of administration, the decrease in estimated glomerular filtration rate became remarkable. Grade 3 hypertension occurred in 94.1% (16\/17) of patients, of whom 66.8% (11\/16) developed intolerable grade 2 proteinuria at a median interval of 35 days. Of these patients, 54.5% (6\/11) developed intolerable grade 2 CKD at a median interval of 245 days.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This longitudinal study revealed which AEs appeared and when. The findings provide useful information about when and which AEs we should be attentive to during daily practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ajco.14211","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:10:03Z","timestamp":1751267403000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010term Longitudinal Observation of Lenvatinib\u2010associated Adverse Events in Patients With Unresectable Radioiodine\u2010refractory Differentiated Thyroid Cancer"],"prefix":"10.1111","volume":"22","author":[{"given":"Yuka","family":"Aida","sequence":"first","affiliation":[{"name":"Department of Medical Oncology University of Tsukuba Hospital Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University of Tsukuba Hospital Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Tsukuba Hospital Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachie","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery Institute of Medicine, University of Tsukuba Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emika","family":"Ichioka","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery Institute of Medicine, University of Tsukuba Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Iguchi\u2010Manaka","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery Institute of Medicine, University of Tsukuba Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joichi","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Nephrology Institute of Medicine, University of Tsukuba Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Tsukuba Hospital Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery Institute of Medicine, University of Tsukuba Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University of Tsukuba Hospital Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"440","volume-title":"Cancer Chemotherapy, Immunotherapy and Biotherapy","author":"Shah A. N.","year":"2019"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30162-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08622-w"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S326255"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab731"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_24"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.14211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:48:19Z","timestamp":1771238899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ajco.14211"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14211","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"2025-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}